Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Immunotech Laboratories, Inc. (OTC: IMMB).

Full DD Report for IMMB

You must become a subscriber to view this report.

Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report. Get a complete short report on IMMB.

About Immunotech Laboratories, Inc. (OTC: IMMB)

Logo for Immunotech Laboratories, Inc. (OTC: IMMB)

lt p gt Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind. lt br / gt lt br / gt Immunotech s flagship compound ITV is a suspension of Inactivated Pepsin Fragment IPF , which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV and is a purified extract of porcine pepsin. ITV has been shown to modulate the immune system. lt br / gt lt br / gt IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti retrovirals in use today. IPF has not shown to be subject to viral resistance and is cost effective. lt /p gt


Contact Information



Current Management

  • Harry Zhabilov / President, Chief Scientific Officer
  • Harry Zhabilov / Chairman
  • Valentin Dimitrov / Independent Director

Current Share Structure

  • Market Cap: $57,496 - 03/21/2018
  • Authorized: 800,000,000 - 12/31/2016
  • Issue and Outstanding: 574,964,967 - 12/31/2016
  • Float: 70,140,892 - 12/31/2016


Daily Technical Chart for (OTC: IMMB)

Daily Technical Chart for (OTC: IMMB)

Stay tuned for daily updates and more on (OTC: IMMB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: IMMB)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMMB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IMMB and does not buy, sell, or trade any shares of IMMB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: